MedTrace Logo

Spectral Focused Imaging Versus White Light Imaging in Colorectal Adenoma Detection

NCT06603948 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 698

Last updated 2025-07-02

No results posted yet for this study

Summary

Spectral Focused Imaging (SFI) is newly developed image-enhancing endoscopy technology that enhances the contrast of target tissue structures while improving color contrast because spectral signal energy is further concentrated on the absorption peak wavelength of microvessels by using digital spectral processing techniques. This technology, combined in the latest generation SonoScape\'s endoscopes (SonoScape Co, Shenzhen, China) with new high-performance LED illumination system, enhances the visibility of colonic mucosal vessels and might increase the detection rate of colorectal polyps. Data available regarding colorectal polyp or adenoma detection with SFI are encouraging but are scanty and limited to back-to back studies.

This two parallel arms, randomized, multicenter trial is aimed at evaluating whether SFI is superior to WLI endoscopy in terms of adenoma detection

Conditions

  • Colorectal Adenoma

Interventions

DEVICE

Spectral Focused Imaging

Use of SFI for colon inspection during both insertion and withdrawal phase of colonoscopy

DEVICE

White Light Imaging

Use of WLI for colon inspection during both insertion and withdrawal phase of colonoscopy

Sponsors & Collaborators

  • First Affiliated Hospital of Ningbo University

    collaborator NETWORK

  • Nanchong Central Hospital

    collaborator OTHER_GOV

  • First Affiliated Hospital of Xinjiang Medical University

    collaborator OTHER

  • West China Forth Hospital

    collaborator UNKNOWN

  • People's Hospital of Guangxi Zhuang Autonomous Region

    collaborator OTHER

  • Seventh Medical Center of PLA Army General Hospital

    collaborator OTHER

  • Tongji Hospital

    collaborator OTHER

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-07
Primary Completion
2025-04-30
Completion
2025-06-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06603948 on ClinicalTrials.gov